References
- Global Health Data Exchange: GBD results tool. [cited 2020 Oct 1]. Available from: http://ghdx.healthdata.org/gbd-results-tool?params=gbd-api-2017-permalink/7370f9af81d6bc6eb855f6f4b122eacf.
- Lad DP, Malhotra P, Khadwal A, et al. Reduced dose ibrutinib due to financial toxicity in CLL. Indian J Hematol Blood Transfus. 2019;35(2):260–264.
- Tejaswi V, Lad DP, Jindal N, et al. Chronic lymphocytic leukemia: real-world data from India. J Clin Oncol Glob Oncol. 2020;6:866–872.
- Egle A, Pleyer L, Melchardt T, et al. Remission maintenance treatment options in chronic lymphocytic leukemia. Cancer Treat Rev. 2018;70:56–66.
- Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol. 2008;26(9):1544–1552.
- Mato AR, Foon KA, Feldman T, et al. Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia. Am J Hematol. 2015;90(6):487–492.
- Fink AM, Bahlo J, Robrecht S, et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol. 2017;4(10):e475–e86.
- Byrd JC, Ruppert AS, Heerema NA, et al. Lenalidomide consolidation benefits patients with CLL receiving chemo-immunotherapy: results for CALGB 10404 (Alliance). Blood Advances. 2018;2(14):1705–1718.
- Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760.
- National Cancer I. Common terminology criteria for adverse events (CTCAE); 2010.
- Youron P, Singh C, Jindal N, et al. Quality of life in patients of chronic lymphocytic leukemia using the EORTC QLQ-C30 and QLQ-CLL17 questionnaire. EurJ Haematol. 2020;105:755–762.
- National guidelines for ethics committees reviewing biomedical & health research during covid-19 pandemic. [cited 2020 Aug 20]. Available from: https://ethics.ncdirindia.org//asset/pdf/EC_Guidance_COVID19.pdf.
- GDP per capita (current US$). Available from: https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=IN
- Egle A, Steurer M, Melchardt T, et al. Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. Ann Hematol. 2018;97(10):1825–1839.
- Kater AP, van Oers MHJ, van Norden Y, et al. Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia. Haematologica. 2019;104(1):147–154.